Skip to content

Online Treatment of Cognitive Impairment and Insomnia in Cancer Survivors

A Randomized Controlled Trial of Online Cognitive Behavior Therapy for Insomnia (CBT-I) and Perceived Cognitive Impairment (PCI) in Cancer Survivors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04026048
Enrollment
132
Registered
2019-07-19
Start date
2019-09-01
Completion date
2023-06-30
Last updated
2025-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Cognitive Impairment, Insomnia

Keywords

Cognitive Behaviour Therapy for Insomnia, CBT-I, Cancer, Insomnia, Sleep, Perceived Cognitive Impairment

Brief summary

The investigators will answer the question of whether treating insomnia using Cognitive Behavior Therapy for Insomnia (CBT-I) can improve perceived cognitive impairment (PCI) in cancer survivors compared to a waitlist control group. The investigators will recruit 124 people with insomnia and cognitive complaints who have completed cancer treatment at least 6 months prior to the study.

Detailed description

The investigators will conduct a randomized controlled trial of immediate treatment with CBT-I compared to a delayed treatment group with 124 cancer survivors who have completed primary treatment at least 6 months prior and report PCI and insomnia. Participants who are randomized to the immediate treatment group will receive CBT-I over the course of seven weekly one hour sessions, after which the delayed treatment group will receive the intervention. Both groups will complete follow up assessments three and six months after completing treatment. PCI will be assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) as the primary outcome. To provide an objective assessment of cognition, the investigators have included the neurocognitive measures recommended by the International Cognition and Cancer Task Force. Other measures will include fatigue, anxiety, depression, and work productivity. The investigators hypothesize that the online CBT-I group will report significantly greater improvements in perceived cognitive function compared to the waitlist control immediately post-treatment (primary endpoint). The investigators also hypothesize that these improvements will be maintained up at 6-months follow up (secondary endpoint).

Interventions

CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Memorial University of Newfoundland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for individuals with non-hematological malignancies: * Men and women who are easily able to understand and read English * No current evidence of cancer or clinically stable/inactive disease * Received and completed all adjuvant treatments at least 6 months prior to study entry to allow for neural stabilization and recovery * Self-reported PCI as indicated by a score of sometimes or higher (quite a lot or always) on at least two out of three questions that assess memory, concentration, and attention * Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for insomnia disorder and have a score of 8 or greater on the Insomnia Severity Index (ISI) * Have good performance status as indicated by an Eastern Cooperative Oncology Group (ECOG) score of 0-2 * Have high-speed internet connection, webcam, and are fluent using the internet Inclusion Criteria for individuals with hematological malignancies: * Men and women who are easily able to understand and read English * A diagnosis of a hematological malignancy currently in remission * Completed cancer treatments including transplant, chemotherapy and/or immunotherapy at least 6 months prior to study entry * Self-reported PCI as indicated by a score of sometimes or higher (quite a lot or always) on at least two out of three questions that assess memory, concentration, and attention * Meet the DSM-5 criteria for insomnia disorder and have a score of 8 or greater on the Insomnia Severity Index * Have good performance status as indicated by an ECOG score of 0-2 * Have high-speed internet connection, webcam, and are fluent using the internet

Exclusion criteria

for individuals with and without hematological malignancies: * Another sleep disorder, besides insomnia, that is not adequately treated (ie: untreated obstructive sleep apnea) * The presence of another psychological disorder that is not currently stable and/or would impair the ability to participate in the study * A major sensory deficit (e.g. blindness) * A neurologic or major medical condition known to affect cognitive function (e.g., Parkinson's) * A history of cranial radiation * A history of any other condition that may affect cognitive functioning (e.g., traumatic brain injury) * Previous experience with CBT-I Other considerations: * Participants will not be excluded for using psychotropic medication prior to study entry (e.g. antidepressants) provided that the dose was not recently altered (stable over the previous 6 weeks) * Considering the potential for prescription of medications to help with sleep (e.g. hypnotics, sedatives, and antidepressants) within the cancer population, medication use throughout the study will be tracked and adjusted for in the statistical analysis

Design outcomes

Primary

MeasureTime frameDescription
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upThe FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale

Secondary

MeasureTime frameDescription
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upSleep efficiency is the percentage of time spent asleep while in bed. It is calculated by dividing the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes). The unit of measure is a percentage and is averaged over the whole week for the total sleep efficiency score.
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upThe sleep diary will be used to calculate sleep-onset latency, which is the length of time that it takes to accomplish the transition from full wakefulness to sleep. The unit of measure is minutes and is averaged over the whole week for the total sleep onset latency score.
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upThe sleep diary will be used to calculate wake after sleep onset, which refers to periods of wakefulness occurring after defined sleep onset. The score is reported in minutes and is averaged over the whole week for the total wake after sleep onset.
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upThe sleep diary will be used to calculate total sleep time. The score is reported in minutes and is averaged over the whole week for the total sleep time.
Hospital Anxiety and Depression Scale (HADS)Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upAnxiety and Depression will be measured using the HADS, which is a 14-item, self-rated instrument for anxiety (7 items) and depression (7 items) symptoms in the past week and has been extensively used in people with cancer. Scores range from 0-21 with below 7 indicating a non-case and the higher the score indicates greater symptom severity.
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upFatigue will be measured using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), which is a 30 item self-report measure comprised of five subscales (general, emotional, physical, mental, vigor) and a total fatigue score. Each subscale score ranges from 0 to 24. The Total MSFI-SF score is calculated by adding the general, physical, emotional and mental subscale scores and subtracting vigor subscale score. Total MFSI-SF score ranges from -24 to 96 with a higher score indicating higher levels of cancer-related fatigue experienced by the patient.
The Insomnia Severity Index (ISI)Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upThe ISI is designed to specifically assess the severity of insomnia symptoms, the impact on daytime functioning, and the amount of associated distress. The ISI has 7 questions, which are summed to compute a total score. The range of the ISI is 0-28 with the higher the value, the more severe the insomnia severity.
The Controlled Oral Word Association Test (COWAT)Change from Baseline to Week 8, 3 month follow up, 6 month follow upThe COWAT is a measure of verbal fluency, cognitive and motor speed, cognitive flexibility, strategy utilization, suppression of interference, and response inhibition. The total score is the total number of different words produced for all three letters in a timeframe of 3 minutes (1 minute for each letter). The scores are adjusted based on age and education level. A greater score indicates better verbal fluency. A score less then 33 indicates below average performance, scores between 34 and 45 indicate average performance, and scores greater than 45 are above average, with scores greater than 52 indicate superior performance. A minimum score is 0 (no words produced) and there is no set maximum score, as it depends on how many words can be produced in the given time frame.
The Digit SpanChange from Baseline to Week 8, 3 month follow up, 6 month follow upThe Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scale (WMS). Part A of digit span (the forward span) captures attention efficiency and capacity, and part B (the backward span) is an executive task dependent on working memory. The Digit Span subtest will be scored as one summary value. The unit of measure is the total recall. Scores on this measure range from 0-48, where greater scores indicates greater attention efficiency, capacity and working memory.
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)Change from Baseline to Week 8, 3 month follow up, 6 month follow upThe Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) is composed of 75 items within nine non-overlapping theoretically and empirically derived clinical scales. It has 2 broad indexes (Behavioural Regulation and Metacognition), an overall summary score, and three validity scales. This analysis examines the overall summary score. T scores (M = 50, SD = 10; transformations of the raw scale scores) are used to interpret the individual's level of executive functioning. Traditionally, T scores at or above 65 are considered clinically significant. Greater scores indicate greater deficits in executive functioning.
The Work Productivity and Activity Impairment (WPAI)Change from Baseline to Week 8, 3 month follow up, 6 month follow upThe WPAI questionnaire was developed for the purpose of collecting productivity loss data within clinical trials and is suitable for direct translation into a monetary figure. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Credibility/Expectancy Questionnaire (CEQ)BaselineThe Credibility/Expectancy Questionnaire (CEQ) is a 6-item questionnaire that captures both credibility beliefs and outcome expectancy. Questions on this scale are rated on a 1-to-9 point or 0-100% Likert scale, depending on the exact question. The scale was adapted to separately assess: (1) credibility beliefs for insomnia; (2) credibility beliefs for PCI; (3) expectancy beliefs for insomnia; and (4) expectancy beliefs for PCI. Since the CEQ utilizes two scales during the administration (1-9, and 0-100%), a composite score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor yielding total scores, where higher values indicate stronger credibility and expectancy beliefs. Credibility beliefs scores ranged from 0 to 23 and expectancy beliefs scores ranged from 0 to 27.
The Hopkins Verbal Learning Test-Revised (HVLT-R)Change from Baseline to Week 8, 3 month follow up, 6 month follow upThe Hopkins Verbal Learning Test-Revised (HVLT-R) is a brief assessment of verbal learning and memory (immediate recall, delayed recall, delayed recognition). When scoring the HVLT-R, the three learning trials are combined to calculate a total recall score; the delayed recall trial creates the delayed recall score; the retention (%) score is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. These scores are then converted to an age-based T score (Mean=50, SD=10). Higher scores represent better verbal learning and memory.

Countries

Canada

Participant flow

Participants by arm

ArmCount
Cognitive Behaviour Therapy for Insomnia (CBT-I)
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
63
Waitlist Control Group
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
69
Total132

Baseline characteristics

CharacteristicWaitlist Control GroupTotalCognitive Behaviour Therapy for Insomnia (CBT-I)
Age, Continuous61.25 years
STANDARD_DEVIATION 10.6
60.28 years
STANDARD_DEVIATION 11.26
59.21 years
STANDARD_DEVIATION 11.93
Baseline insomnia score17.88 units on a scale
STANDARD_DEVIATION 3.83
17.59 units on a scale
STANDARD_DEVIATION 3.69
17.27 units on a scale
STANDARD_DEVIATION 3.53
Baseline perceived cognitive impairment score38.80 units on a scale
STANDARD_DEVIATION 13.86
39.1 units on a scale
STANDARD_DEVIATION 13.1
39.40 units on a scale
STANDARD_DEVIATION 12.32
Cancer stage
Stage 0/in situ
3 Participants4 Participants1 Participants
Cancer stage
Stage I
15 Participants27 Participants12 Participants
Cancer stage
Stage II
10 Participants23 Participants13 Participants
Cancer stage
Stage III
13 Participants28 Participants15 Participants
Cancer stage
Stage IV
5 Participants7 Participants2 Participants
Cancer stage
Unknown/not applicable
23 Participants43 Participants20 Participants
Cancer treatments received
Chemotherapy
35 Participants81 Participants46 Participants
Cancer treatments received
Hormone therapy
29 Participants42 Participants13 Participants
Cancer treatments received
Other
4 Participants8 Participants4 Participants
Cancer treatments received
Radiation
38 Participants76 Participants38 Participants
Cancer treatments received
Surgery
65 Participants117 Participants52 Participants
Cancer type
Breast
29 Participants54 Participants25 Participants
Cancer type
Female genitourinary
5 Participants11 Participants6 Participants
Cancer type
GI tract
5 Participants7 Participants2 Participants
Cancer type
Hematologic
5 Participants16 Participants11 Participants
Cancer type
Multiple types
12 Participants23 Participants11 Participants
Cancer type
Other
2 Participants6 Participants4 Participants
Cancer type
Prostate and male genitourinary
5 Participants7 Participants2 Participants
Cancer type
Skin
6 Participants8 Participants2 Participants
Employment status
Not working/retired
48 Participants84 Participants36 Participants
Employment status
Working (part or full-time)
21 Participants48 Participants27 Participants
Race/Ethnicity, Customized
BIPOC
4 Participants10 Participants6 Participants
Race/Ethnicity, Customized
White
65 Participants122 Participants57 Participants
Region of Enrollment
Canada
69 participants132 participants63 participants
Sex: Female, Male
Female
52 Participants102 Participants50 Participants
Sex: Female, Male
Male
17 Participants30 Participants13 Participants
Time since cancer diagnosis (years)
≥10
26 Participants54 Participants28 Participants
Time since cancer diagnosis (years)
<2
7 Participants14 Participants7 Participants
Time since cancer diagnosis (years)
2-4
21 Participants32 Participants11 Participants
Time since cancer diagnosis (years)
5-9
14 Participants31 Participants17 Participants
Time since insomnia began (months)88.56 months
STANDARD_DEVIATION 79.23
93.63 months
STANDARD_DEVIATION 75.39
99.19 months
STANDARD_DEVIATION 71.17
Years of education
College (12-14 years)
24 Participants42 Participants18 Participants
Years of education
High school (≤11 years)
2 Participants6 Participants4 Participants
Years of education
Postsecondary (≥15 years)
43 Participants84 Participants41 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 630 / 69
other
Total, other adverse events
12 / 6314 / 69
serious
Total, serious adverse events
2 / 632 / 69

Outcome results

Primary

The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3

The FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3Baseline39.39 score on a scaleStandard Deviation 12.32
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 38 weeks53.44 score on a scaleStandard Deviation 12.01
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 34 weeks48.28 score on a scaleStandard Deviation 11.89
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 36 months follow-up52.47 score on a scaleStandard Deviation 12.89
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 33 months follow-up53.16 score on a scaleStandard Deviation 11.37
Waitlist Control GroupThe Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 36 months follow-up51.46 score on a scaleStandard Deviation 14.1
Waitlist Control GroupThe Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 33 months follow-up46.21 score on a scaleStandard Deviation 19.64
Waitlist Control GroupThe Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3Baseline38.79 score on a scaleStandard Deviation 13.85
Waitlist Control GroupThe Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 34 weeks44.71 score on a scaleStandard Deviation 13.84
Waitlist Control GroupThe Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 38 weeks43.00 score on a scaleStandard Deviation 12.89
Secondary

Credibility/Expectancy Questionnaire (CEQ)

The Credibility/Expectancy Questionnaire (CEQ) is a 6-item questionnaire that captures both credibility beliefs and outcome expectancy. Questions on this scale are rated on a 1-to-9 point or 0-100% Likert scale, depending on the exact question. The scale was adapted to separately assess: (1) credibility beliefs for insomnia; (2) credibility beliefs for PCI; (3) expectancy beliefs for insomnia; and (4) expectancy beliefs for PCI. Since the CEQ utilizes two scales during the administration (1-9, and 0-100%), a composite score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor yielding total scores, where higher values indicate stronger credibility and expectancy beliefs. Credibility beliefs scores ranged from 0 to 23 and expectancy beliefs scores ranged from 0 to 27.

Time frame: Baseline

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)Credibility/Expectancy Questionnaire (CEQ)Baseline expectancy19.68 scores on a scaleStandard Deviation 4.48
Cognitive Behaviour Therapy for Insomnia (CBT-I)Credibility/Expectancy Questionnaire (CEQ)Baseline credibility15.37 scores on a scaleStandard Deviation 4.42
Waitlist Control GroupCredibility/Expectancy Questionnaire (CEQ)Baseline credibility16.43 scores on a scaleStandard Deviation 3.94
Waitlist Control GroupCredibility/Expectancy Questionnaire (CEQ)Baseline expectancy20.28 scores on a scaleStandard Deviation 4.19
Secondary

Hospital Anxiety and Depression Scale (HADS)

Anxiety and Depression will be measured using the HADS, which is a 14-item, self-rated instrument for anxiety (7 items) and depression (7 items) symptoms in the past week and has been extensively used in people with cancer. Scores range from 0-21 with below 7 indicating a non-case and the higher the score indicates greater symptom severity.

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)3 month follow-up depression3.57 score on a scaleStandard Deviation 2.88
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)4 weeks depression4.45 score on a scaleStandard Deviation 3.48
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)6 month follow-up depression4.24 score on a scaleStandard Deviation 3.52
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)8 weeks depression3.14 score on a scaleStandard Deviation 3.29
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)Baseline anxiety9.33 score on a scaleStandard Deviation 3.48
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)8 weeks anxiety5.89 score on a scaleStandard Deviation 3.31
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)4 weeks anxiety6.88 score on a scaleStandard Deviation 3.25
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)3 month follow-up anxiety6.04 score on a scaleStandard Deviation 3.79
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)6 month follow-up anxiety6.18 score on a scaleStandard Deviation 4.33
Cognitive Behaviour Therapy for Insomnia (CBT-I)Hospital Anxiety and Depression Scale (HADS)Baseline depression7.90 score on a scaleStandard Deviation 2.88
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)6 month follow-up anxiety5.67 score on a scaleStandard Deviation 3.82
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)Baseline depression6.39 score on a scaleStandard Deviation 3.72
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)4 weeks depression4.63 score on a scaleStandard Deviation 3.65
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)3 month follow-up depression5.90 score on a scaleStandard Deviation 2.36
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)Baseline anxiety8.70 score on a scaleStandard Deviation 4.24
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)4 weeks anxiety7.97 score on a scaleStandard Deviation 3.78
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)3 month follow-up anxiety5.97 score on a scaleStandard Deviation 4.41
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)8 weeks depression3.09 score on a scaleStandard Deviation 3.14
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)6 month follow-up depression3.30 score on a scaleStandard Deviation 2.99
Waitlist Control GroupHospital Anxiety and Depression Scale (HADS)8 weeks anxiety7.08 score on a scaleStandard Deviation 4.47
Secondary

Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)

Fatigue will be measured using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), which is a 30 item self-report measure comprised of five subscales (general, emotional, physical, mental, vigor) and a total fatigue score. Each subscale score ranges from 0 to 24. The Total MSFI-SF score is calculated by adding the general, physical, emotional and mental subscale scores and subtracting vigor subscale score. Total MFSI-SF score ranges from -24 to 96 with a higher score indicating higher levels of cancer-related fatigue experienced by the patient.

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)8 weeks4.72 score on a scaleStandard Deviation 16.17
Cognitive Behaviour Therapy for Insomnia (CBT-I)Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)Baseline29.57 score on a scaleStandard Deviation 16.75
Cognitive Behaviour Therapy for Insomnia (CBT-I)Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)3 month follow-up9.13 score on a scaleStandard Deviation 16.44
Cognitive Behaviour Therapy for Insomnia (CBT-I)Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)6 month follow-up10.04 score on a scaleStandard Deviation 18.13
Cognitive Behaviour Therapy for Insomnia (CBT-I)Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)4 weeks16.52 score on a scaleStandard Deviation 17.5
Waitlist Control GroupMultidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)6 month follow-up5.95 score on a scaleStandard Deviation 17.65
Waitlist Control GroupMultidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)3 month follow-up6.79 score on a scaleStandard Deviation 18.41
Waitlist Control GroupMultidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)Baseline26.64 score on a scaleStandard Deviation 19.38
Waitlist Control GroupMultidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)8 weeks6.05 score on a scaleStandard Deviation 19.62
Waitlist Control GroupMultidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)4 weeks17.17 score on a scaleStandard Deviation 20.49
Secondary

Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)

Sleep efficiency is the percentage of time spent asleep while in bed. It is calculated by dividing the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes). The unit of measure is a percentage and is averaged over the whole week for the total sleep efficiency score.

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)3 month follow-up88.58 percentage of sleep efficiencyStandard Deviation 8.02
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)4 weeks87.18 percentage of sleep efficiencyStandard Deviation 8.17
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)Baseline73.22 percentage of sleep efficiencyStandard Deviation 12.45
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)6 month follow-up88.52 percentage of sleep efficiencyStandard Deviation 7.88
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)8 weeks89.63 percentage of sleep efficiencyStandard Deviation 7.1
Waitlist Control GroupSleep Efficiency Measured by The Consensus Sleep Diary (CSD)6 month follow-up87.83 percentage of sleep efficiencyStandard Deviation 6.81
Waitlist Control GroupSleep Efficiency Measured by The Consensus Sleep Diary (CSD)8 weeks89.33 percentage of sleep efficiencyStandard Deviation 6.41
Waitlist Control GroupSleep Efficiency Measured by The Consensus Sleep Diary (CSD)3 month follow-up87.22 percentage of sleep efficiencyStandard Deviation 7.62
Waitlist Control GroupSleep Efficiency Measured by The Consensus Sleep Diary (CSD)Baseline74.03 percentage of sleep efficiencyStandard Deviation 13.58
Waitlist Control GroupSleep Efficiency Measured by The Consensus Sleep Diary (CSD)4 weeks88.10 percentage of sleep efficiencyStandard Deviation 6.24
Secondary

Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)

The sleep diary will be used to calculate sleep-onset latency, which is the length of time that it takes to accomplish the transition from full wakefulness to sleep. The unit of measure is minutes and is averaged over the whole week for the total sleep onset latency score.

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)Baseline40.56 minutesStandard Deviation 32.4
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)3 month follow-up16.70 minutesStandard Deviation 18.44
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)8 weeks12.68 minutesStandard Deviation 8.98
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)6 month follow-up14.71 minutesStandard Deviation 10.41
Cognitive Behaviour Therapy for Insomnia (CBT-I)Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)4 weeks16.68 minutesStandard Deviation 15.73
Waitlist Control GroupSleep-onset Latency Measured by The Consensus Sleep Diary (CSD)6 month follow-up22.26 minutesStandard Deviation 20.24
Waitlist Control GroupSleep-onset Latency Measured by The Consensus Sleep Diary (CSD)4 weeks16.98 minutesStandard Deviation 13.43
Waitlist Control GroupSleep-onset Latency Measured by The Consensus Sleep Diary (CSD)Baseline41.48 minutesStandard Deviation 34.22
Waitlist Control GroupSleep-onset Latency Measured by The Consensus Sleep Diary (CSD)8 weeks15.41 minutesStandard Deviation 11.7
Waitlist Control GroupSleep-onset Latency Measured by The Consensus Sleep Diary (CSD)3 month follow-up21.43 minutesStandard Deviation 16.04
Secondary

The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)

The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) is composed of 75 items within nine non-overlapping theoretically and empirically derived clinical scales. It has 2 broad indexes (Behavioural Regulation and Metacognition), an overall summary score, and three validity scales. This analysis examines the overall summary score. T scores (M = 50, SD = 10; transformations of the raw scale scores) are used to interpret the individual's level of executive functioning. Traditionally, T scores at or above 65 are considered clinically significant. Greater scores indicate greater deficits in executive functioning.

Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)8 weeks51.14 t scoreStandard Deviation 10.72
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)Baseline60.37 t scoreStandard Deviation 10.31
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)3 month follow-up50.13 t scoreStandard Deviation 10.67
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)6 month follow-up50.65 t scoreStandard Deviation 10.39
Waitlist Control GroupThe Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)6 month follow-up52.54 t scoreStandard Deviation 13.6
Waitlist Control GroupThe Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)8 weeks52.41 t scoreStandard Deviation 11.3
Waitlist Control GroupThe Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)3 month follow-up51.54 t scoreStandard Deviation 11.08
Waitlist Control GroupThe Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)Baseline59.13 t scoreStandard Deviation 11.28
Secondary

The Controlled Oral Word Association Test (COWAT)

The COWAT is a measure of verbal fluency, cognitive and motor speed, cognitive flexibility, strategy utilization, suppression of interference, and response inhibition. The total score is the total number of different words produced for all three letters in a timeframe of 3 minutes (1 minute for each letter). The scores are adjusted based on age and education level. A greater score indicates better verbal fluency. A score less then 33 indicates below average performance, scores between 34 and 45 indicate average performance, and scores greater than 45 are above average, with scores greater than 52 indicate superior performance. A minimum score is 0 (no words produced) and there is no set maximum score, as it depends on how many words can be produced in the given time frame.

Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Controlled Oral Word Association Test (COWAT)3 month follow-up51.04 adj score on a scaleStandard Deviation 12.91
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Controlled Oral Word Association Test (COWAT)8 weeks46.77 adj score on a scaleStandard Deviation 11.12
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Controlled Oral Word Association Test (COWAT)6 month follow-up50.02 adj score on a scaleStandard Deviation 11.44
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Controlled Oral Word Association Test (COWAT)Baseline47.14 adj score on a scaleStandard Deviation 11.48
Waitlist Control GroupThe Controlled Oral Word Association Test (COWAT)6 month follow-up49.62 adj score on a scaleStandard Deviation 13.87
Waitlist Control GroupThe Controlled Oral Word Association Test (COWAT)8 weeks47.50 adj score on a scaleStandard Deviation 13.61
Waitlist Control GroupThe Controlled Oral Word Association Test (COWAT)3 month follow-up48.42 adj score on a scaleStandard Deviation 12.2
Waitlist Control GroupThe Controlled Oral Word Association Test (COWAT)Baseline44.41 adj score on a scaleStandard Deviation 12.31
Secondary

The Digit Span

The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scale (WMS). Part A of digit span (the forward span) captures attention efficiency and capacity, and part B (the backward span) is an executive task dependent on working memory. The Digit Span subtest will be scored as one summary value. The unit of measure is the total recall. Scores on this measure range from 0-48, where greater scores indicates greater attention efficiency, capacity and working memory.

Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Digit Span8 weeks30.11 score on a scaleStandard Deviation 4.82
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Digit Span6 month follow-up31.13 score on a scaleStandard Deviation 4.38
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Digit Span3 month follow-up30.73 score on a scaleStandard Deviation 4.97
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Digit SpanBaseline28.49 score on a scaleStandard Deviation 4.06
Waitlist Control GroupThe Digit Span6 month follow-up28.38 score on a scaleStandard Deviation 5.72
Waitlist Control GroupThe Digit Span3 month follow-up28.17 score on a scaleStandard Deviation 6.14
Waitlist Control GroupThe Digit Span8 weeks27.97 score on a scaleStandard Deviation 5.15
Waitlist Control GroupThe Digit SpanBaseline28.44 score on a scaleStandard Deviation 5.03
Secondary

The Hopkins Verbal Learning Test-Revised (HVLT-R)

The Hopkins Verbal Learning Test-Revised (HVLT-R) is a brief assessment of verbal learning and memory (immediate recall, delayed recall, delayed recognition). When scoring the HVLT-R, the three learning trials are combined to calculate a total recall score; the delayed recall trial creates the delayed recall score; the retention (%) score is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. These scores are then converted to an age-based T score (Mean=50, SD=10). Higher scores represent better verbal learning and memory.

Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Hopkins Verbal Learning Test-Revised (HVLT-R)Baseline49.84 t scoreStandard Deviation 10.72
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Hopkins Verbal Learning Test-Revised (HVLT-R)8 weeks49.11 t scoreStandard Deviation 11.63
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Hopkins Verbal Learning Test-Revised (HVLT-R)3 month follow-up54.25 t scoreStandard Deviation 9.66
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Hopkins Verbal Learning Test-Revised (HVLT-R)6 month follow-up55.94 t scoreStandard Deviation 10.67
Waitlist Control GroupThe Hopkins Verbal Learning Test-Revised (HVLT-R)6 month follow-up54.54 t scoreStandard Deviation 10.94
Waitlist Control GroupThe Hopkins Verbal Learning Test-Revised (HVLT-R)3 month follow-up53.36 t scoreStandard Deviation 11.47
Waitlist Control GroupThe Hopkins Verbal Learning Test-Revised (HVLT-R)8 weeks50.19 t scoreStandard Deviation 10.95
Waitlist Control GroupThe Hopkins Verbal Learning Test-Revised (HVLT-R)Baseline49.22 t scoreStandard Deviation 12.64
Secondary

The Insomnia Severity Index (ISI)

The ISI is designed to specifically assess the severity of insomnia symptoms, the impact on daytime functioning, and the amount of associated distress. The ISI has 7 questions, which are summed to compute a total score. The range of the ISI is 0-28 with the higher the value, the more severe the insomnia severity.

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Insomnia Severity Index (ISI)4 weeks9.67 score on Insomnai Severity IndexStandard Deviation 4.01
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Insomnia Severity Index (ISI)3 months follow-up7.11 score on Insomnai Severity IndexStandard Deviation 4.84
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Insomnia Severity Index (ISI)8 weeks6.03 score on Insomnai Severity IndexStandard Deviation 3.9
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Insomnia Severity Index (ISI)6 months follow-up7.94 score on Insomnai Severity IndexStandard Deviation 5.6
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Insomnia Severity Index (ISI)Basline17.27 score on Insomnai Severity IndexStandard Deviation 3.53
Waitlist Control GroupThe Insomnia Severity Index (ISI)6 months follow-up6.28 score on Insomnai Severity IndexStandard Deviation 4.23
Waitlist Control GroupThe Insomnia Severity Index (ISI)Basline15.06 score on Insomnai Severity IndexStandard Deviation 4.57
Waitlist Control GroupThe Insomnia Severity Index (ISI)4 weeks9.77 score on Insomnai Severity IndexStandard Deviation 4.81
Waitlist Control GroupThe Insomnia Severity Index (ISI)8 weeks6.34 score on Insomnai Severity IndexStandard Deviation 4.3
Waitlist Control GroupThe Insomnia Severity Index (ISI)3 months follow-up6.37 score on Insomnai Severity IndexStandard Deviation 4.6
Secondary

The Work Productivity and Activity Impairment (WPAI)

The WPAI questionnaire was developed for the purpose of collecting productivity loss data within clinical trials and is suitable for direct translation into a monetary figure. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Work Productivity and Activity Impairment (WPAI)Baseline23.33 percentage of work productivity lossStandard Deviation 34.04
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Work Productivity and Activity Impairment (WPAI)8 weeks7.42 percentage of work productivity lossStandard Deviation 21.48
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Work Productivity and Activity Impairment (WPAI)3 month follow-up6.25 percentage of work productivity lossStandard Deviation 20.14
Cognitive Behaviour Therapy for Insomnia (CBT-I)The Work Productivity and Activity Impairment (WPAI)6 month follow-up5.77 percentage of work productivity lossStandard Deviation 19.36
Waitlist Control GroupThe Work Productivity and Activity Impairment (WPAI)6 month follow-up5.63 percentage of work productivity lossStandard Deviation 19.92
Waitlist Control GroupThe Work Productivity and Activity Impairment (WPAI)8 weeks11.54 percentage of work productivity lossStandard Deviation 28.05
Waitlist Control GroupThe Work Productivity and Activity Impairment (WPAI)Baseline18.28 percentage of work productivity lossStandard Deviation 31.29
Waitlist Control GroupThe Work Productivity and Activity Impairment (WPAI)3 month follow-up5.85 percentage of work productivity lossStandard Deviation 20.37
Secondary

Total Sleep Time Measured by The Consensus Sleep Diary (CSD):

The sleep diary will be used to calculate total sleep time. The score is reported in minutes and is averaged over the whole week for the total sleep time.

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)Total Sleep Time Measured by The Consensus Sleep Diary (CSD):4 weeks358.77 minutesStandard Deviation 64.05
Cognitive Behaviour Therapy for Insomnia (CBT-I)Total Sleep Time Measured by The Consensus Sleep Diary (CSD):3 month follow-up412.06 minutesStandard Deviation 68.69
Cognitive Behaviour Therapy for Insomnia (CBT-I)Total Sleep Time Measured by The Consensus Sleep Diary (CSD):8 weeks392.14 minutesStandard Deviation 52.52
Cognitive Behaviour Therapy for Insomnia (CBT-I)Total Sleep Time Measured by The Consensus Sleep Diary (CSD):6 month follow-up401.42 minutesStandard Deviation 84.67
Cognitive Behaviour Therapy for Insomnia (CBT-I)Total Sleep Time Measured by The Consensus Sleep Diary (CSD):Baseline370.06 minutesStandard Deviation 67.72
Waitlist Control GroupTotal Sleep Time Measured by The Consensus Sleep Diary (CSD):6 month follow-up429.24 minutesStandard Deviation 56.6
Waitlist Control GroupTotal Sleep Time Measured by The Consensus Sleep Diary (CSD):Baseline378.41 minutesStandard Deviation 81.09
Waitlist Control GroupTotal Sleep Time Measured by The Consensus Sleep Diary (CSD):4 weeks376.08 minutesStandard Deviation 59.71
Waitlist Control GroupTotal Sleep Time Measured by The Consensus Sleep Diary (CSD):8 weeks406.40 minutesStandard Deviation 57.11
Waitlist Control GroupTotal Sleep Time Measured by The Consensus Sleep Diary (CSD):3 month follow-up418.81 minutesStandard Deviation 62.12
Secondary

Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)

The sleep diary will be used to calculate wake after sleep onset, which refers to periods of wakefulness occurring after defined sleep onset. The score is reported in minutes and is averaged over the whole week for the total wake after sleep onset.

Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

ArmMeasureGroupValue (MEAN)Dispersion
Cognitive Behaviour Therapy for Insomnia (CBT-I)Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)4 weeks23.32 minutesStandard Deviation 17.3
Cognitive Behaviour Therapy for Insomnia (CBT-I)Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)3 month follow-up20.06 minutesStandard Deviation 20.46
Cognitive Behaviour Therapy for Insomnia (CBT-I)Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)8 weeks21.84 minutesStandard Deviation 19.8
Cognitive Behaviour Therapy for Insomnia (CBT-I)Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)6 month follow-up21.46 minutesStandard Deviation 20.24
Cognitive Behaviour Therapy for Insomnia (CBT-I)Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)Baseline63.29 minutesStandard Deviation 41.99
Waitlist Control GroupWake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)6 month follow-up21.85 minutesStandard Deviation 20.34
Waitlist Control GroupWake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)Baseline50.80 minutesStandard Deviation 34.14
Waitlist Control GroupWake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)4 weeks19.90 minutesStandard Deviation 14.87
Waitlist Control GroupWake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)8 weeks20.06 minutesStandard Deviation 18.95
Waitlist Control GroupWake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)3 month follow-up22.87 minutesStandard Deviation 19.86

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026